Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01179048 · ClinicalTrials.gov registry record · Phase 3
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,341
- Enrollment target
NCT01179048 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 9,341 participants.
The verdict
NCT01179048, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,341 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,341 participants |
| Start Date | 2010-08-31 |
| Est. Completion | 2015-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01179048
The ClinicalTrials.gov registry entry for NCT01179048 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01179048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01179048 about?
NCT01179048 is a clinical study titled "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results". This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
What is the current status of trial NCT01179048?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,341 participants. The study started on 2010-08-31. Estimated completion is 2015-12-17.
What interventions are being tested in trial NCT01179048?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01179048?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.